Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Oct;314(8):729-738.
doi: 10.1007/s00403-021-02277-0. Epub 2021 Sep 14.

Role of botulinum toxin A in improving facial erythema and skin quality

Affiliations
Review

Role of botulinum toxin A in improving facial erythema and skin quality

Edith Hanna et al. Arch Dermatol Res. 2022 Oct.

Abstract

Botulinum toxin A (BTX-A) injections have become the most popular noninvasive cosmetic procedures performed worldwide. With growing interest, investigators continue to uncover an expanding array of aesthetic indications for BTX-A. Botulinum toxin A has been used off-label in the management of masseter hypertrophy for facial slimming, platysmal bands, nasal 'bunny' lines, perioral rhytides, gummy smile and scars, to name a few. Interestingly, the injection of multiple microdroplets of dilute BTX-A into the dermis, sometimes referred to as 'microbotox', has been investigated as a tool for facial rejuvenation. A handful of prospective studies and case series have demonstrated the benefit of BTX-A in the treatment of facial erythema and improving skin texture. The aim of this review is to summarize and appraise currently available data on the role of BTX-A in treating facial erythema and skin quality, with a special focus on potential pathophysiologic mechanisms.

Keywords: Botulinumtoxin A; Cosmetic dermatology; Facial erythema; Facial rejuvenation; Fillers; Fine lines; General dermatology; Injectables; Medical dermatology; Neuromodulators; Pore size; Rhytids; Rosacea; Sebum production; Skin quality; Wrinkles.

PubMed Disclaimer

References

    1. Eshghi G, Khezrian L, Alirezaei P (2016) Botulinum toxin-a in treatment of facial flushing. Acta Med Iran 54(7):454–457 - PubMed
    1. Dayan SH, Pritzker RN, Arkins JP (2012) A new treatment regimen for rosacea: onabotulinumtoxin A. J Drugs Dermatol 11(12):e76–e79 - PubMed
    1. Kim MJ, Kim JH, Cheon HI, Hur MS, Han SH, Lee YW et al (2019) Assessment of skin physiology change and safety after intradermal injections with botulinum toxin: a randomized, double-blind, placebo-controlled, split-face pilot study in rosacea patients with facial erythema. Dermatol Surg 45(9):1155–1162 - DOI
    1. Bloom BS, Payongayong L, Mourin A, Goldberg DJ (2015) Impact of intradermal abobotulinumtoxin A on facial erythema of rosacea. Dermatol Surg 41:S9-16 - DOI
    1. Park KY, Kwon HJ, Kim JM, Jeong GJ, Kim BJ, Seo SJ et al (2018) A pilot study to evaluate the efficacy and safety of treatment with botulinum toxin in patients with recalcitrant and persistent erythematotelangiectatic rosacea. Ann Dermatol 30(6):688–693 - DOI

Substances

LinkOut - more resources